Previous Close | 0.7000 |
Open | 0.7000 |
Bid | 0.0000 |
Ask | 1.1500 |
Strike | 50.00 |
Expire Date | 2025-01-17 |
Day's Range | 0.7000 - 0.7000 |
Contract Range | N/A |
Volume | |
Open Interest | 104 |
Insmed Inc (INSM) reports robust financial performance and outlines strategic initiatives for upcoming product launches amid competitive challenges.
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from th